Standards for the care of people with cystic fibrosis; establishing and maintaining health [PDF]
Cystic fibrosis; Health; StandardsFibrosis quística; Salud; EstándaresFibrosi quística; Salut; EstàndardsThis is the second in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF.
Addy, Charlotte +31 more
core +4 more sources
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Cystic Fibrosis Liver Tests in a Real-World Cohort with and Without Baseline CFLD [PDF]
, 2021 Megan E. Bowen +4 more
openalex +1 more source
Cystic Fibrosis: New Trends in Therapy Methods
Архивъ внутренней медициныThis review provides information on recent advancements in the treatment of cystic fi brosis and presents interim results from ongoing clinical trials. Various scientifi c databases, including Scopus, Web of Science, and EMBASE, were utilized during the ...
P. A. Suchkova +3 more
doaj +1 more source
Quantification of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor and their active metabolites in plasma using UHPLC-MS/MS:Doors open to the application of therapeutic drug monitoring in cystic fibrosis treatment [PDF]
An ultra-high performance liquid chromatography-tandem mass spectrometry method was developed to quantify the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, tezacaftor, elexacaftor, and lumacaftor and their active ...
Akkerman, Onno W +5 more
core +1 more source
Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice
Acta PsychologicaRecent advances in cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination therapies have markedly improved survival and quality of life for people with cystic fibrosis (CF).
Qian Ge +4 more
doaj +1 more source
High-Dose Inhaled Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia Multivorans in a Patient Receiving Elexacaftor-Tezacaftor-Ivacaftor [PDF]
, 2021 Kelly Gardner +8 more
openalex +1 more source
WS06.04 Lung volumes as possible factors explaining the heterogeneity in the response to elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease [PDF]
, 2023 Chiara Premuda +8 more
openalex +1 more source
The Effect of Elexacaftor/Tezacaftor/Ivacaftor on Hospitalizations and Intravenous Antibiotic Use
, 2022 Éric Walter, Jennifer L. Bass
openalex +2 more sources
CFTR Modulator Therapy in the Treatment of Cystic Fibrosis as Compared to Placebo [PDF]
Objective: To assess the efficacy of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies including ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor combinations in the improvement of lung function in ...
Doody, Rebecca Leigh +1 more
core +1 more source